Despite almost universal testing for human-epidermal-growth-factor-receptor-2 (HER2), many women with a HER2-positive cancer may not receive trastuzumab. Fewer women received the newer gene-expression-profile (GEP) test.
Given the likely proliferation of targeted testing and treatment strategies for cancer, a better understanding of the utilization patterns of human epidermal growth factor receptor 2 (HER2) testing and trastuzumab and newer gene expression profiling (GEP) for risk stratification and chemotherapy decision making are important.
We performed a medical record review of women aged 35 to 65 years diagnosed between 2006 and 2007 with invasive localized breast cancer, identified using claims from a large national health plan (N = 775).
Almost all women received HER2 testing (96.9%), and 24.9% of women with an accepted indication received GEP. Unexplained socioeconomic differences in GEP use were apparent after adjusting for age and clinical characteristics; specifically, GEP use increased with income. For example, those in the lowest income category (<$40,000) were less likely than those with an income of $125,000 or more to receive GEP (odds ratio, 0.34; 95% confidence interval, 0.16 to 0.73). A majority of women (57.7%) with HER2-positive disease received trastuzumab; among these women, differences in age and clinical characteristics were not apparent, although surprisingly, those in the lowest income category were more likely than those in the high-income category to receive trastuzumab (P = .02). Among women who did not have a positive HER2 test, 3.9% still received trastuzumab. Receipt of adjuvant chemotherapy increased as GEP score indicated greater risk of recurrence.
Identifying and eliminating unnecessary variation in the use of these expensive tests and treatments should be part of quality improvement and efficiency programs.
(Am J Manag Care. 2011;17(5 Spec No.):e174-e181)
Despite almost universal testing for HER2, many women with HER2-positive cancer may not receive trastuzumab.
Despite the growing importance of targeted genomically based tests and treatments for cancer, evidence of use in practice is limited.1,2 Understanding these utilization patterns is critical to developing thoughtful healthcare delivery models and policies. Breast cancer care provides 2 key clinical cases for understanding the use of targeted tests and treatments for cancer.
First is the use of human epidermal growth factor receptor 2 (HER2) testing to guide trastuzumab (Herceptin; Genentech, South San Francisco, CA) therapy, one of the most successful evidence-based examples of using a targeted test to determine who should receive a specific therapy. HER2 is an oncogene that is amplified in approximately 25% to 30% of breast cancers and is associated with decreased survival.3 Trastuzumab is a monoclonal antibody targeting HER2. Because the benefits of trastuzumab are highly associated with HER2 status,4-7 professional organizations recommend HER2 testing for all primary breast cancers at diagnosis.8-10 Yet implementation of these guidelines in practice has been complicated.11 Two types of tests have been approved: immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH). IHC is less expensive and more widely available but has poorer reliability.9,12 This has led to debate about the best testing strategy,1,13 fueled by the high cost of the drug.14,15
The second example—gene expression profiling (GEP)—has generated intense interest, because it may improve prognostic information and predict response to adjuvant chemotherapy.16-19 Guidelines suggest that a majority of women with node-negative, estrogen receptor—positive breast cancer should be offered chemotherapy, but because only a minority will experience recurrence, some patients may receive little benefit.10,20 GEP may identify women who are at low risk of recurrence, who may therefore forego chemotherapy.18 Use of GEP to tailor chemotherapy is less firmly established than the use of HER2 testing to guide trastuzumab.
Given the likely proliferation of genomically based testing and treatment strategies for cancer, better understanding of utilization regarding these 2 examples is important. Our objectives were to evaluate use of targeted tests (HER2 and GEP) and the associated treatment decisions (trastuzumab and adjuvant chemotherapy) in clinical practice.
We identified women aged 35 to 65 years with incident breast cancer diagnosed between July 1, 2006, and June 30, 2007, who received health insurance coverage through Aetna (Hartford, CT), a national health benefits company. Potentially eligible women were identified from claims data.21 We included women who were continuously enrolled from 24 months before to 12 months after diagnosis. Records were requested from the primary medical oncologist and surgeon. We initially identified 2121 women in the claims. We requested records until we reached the prespecified sample size determined by our budget of 800 abstracted records. At the time of abstraction, 517 women were found to be ineligible, because they did not have invasive breast cancer (ie, they had carcinoma in situ only). We abstracted medical records for 787 women with invasive breast cancer. Women with abstracted records were not statistically different from the population of eligible women in terms of age, household income, comorbidity, type of breast cancer surgery, or census region, but they were less likely to have health maintenance organization (HMO) plans (29.4% vs 34.6%; P = .01). Because few women (n = 7) had stage IV cancer or were missing stage information (n = 5), we excluded these women to focus on women with early-stage cancer. We abstracted records for 775 women with early-stage cancer.
Although all women received coverage through Aetna, there were 41 different health plan products. All plans provided coverage for these tests and treatments. Oncotype DX (Genomic Health, Redwood City, CA) is the most commonly available commercial GEP test in the United States. Aetna instituted a formal coverage policy for Oncotype DX on December 1, 2006, with the requirement that a woman’s breast cancer be estrogen receptor positive and lymph node negative, with tumor smaller than 1 cm if HER2 positive or of any size if HER2 status is negative, intermediate, or unknown.22 Before Aetna instituted this policy, women may have had claims for Oncotype DX paid on a case by case basis, or they could have paid out of pocket.
Sources of Data
In addition to identifying the cohort, we used claims to determine age, comorbidity,23 and procedure (eg, breastconserving surgery, mastectomy). Data on annual household income, derived from small area estimation,24 were also available. Health plan products were categorized into the following plan types: indemnity, HMO, preferred provider organization, and point of service. There were no differences in referral requirements across plan type for these tests and treatments. Because the average per-member per-month cost (including coinsurance, deductible, and copayment costs) paid by all Aetna members for all outpatient claims incurred in 2009 was lower for HMO plans ($12.20) than for the other plan types ($30.92, point of service; $27.81, indemnity; $23.86, preferred provider organization), we compared women with an HMO plan with those with other plans. Information about race/ethnicity (ie, white, black, Hispanic, or other) was available from health plan records, based on self-reported data from enrollment records (35.2%), or inferred using a proprietary algorithm.24 This algorithm uses small area estimation with data from the current population survey and American community survey, assigning race/ethnicity on the basis of first name, surname, and geographic criteria. In a secondary analysis, we also examined claims data for January 2007 to December 2009 to obtain more recent data on use of GEP and trastuzumab.
A standard abstraction tool was used to collect detailed clinical information, including menopausal status, cancer stage, tumor size, lymph node involvement, estrogen receptor status, use and results of any HER2 or GEP tests, and use of trastuzumab and adjuvant chemotherapy. Medical records were reviewed by trained abstractors contracted through a third-party vendor, who released a de-identified analytic data set to the investigators.
We examined 2 sets of outcomes. First, we examined use of HER2 testing and trastuzumab conditional on HER2 results. We specifically examined type of HER2 test (IHC, FISH, or both). Second, we identified the use of GEP and adjuvant chemotherapy. Patients were considered to have received chemotherapy if they had documentation in their medical records of any chemotherapy medications commonly administered for breast cancer (ie, adriamycin, carboplatin, cyclophosphamide, docetaxel, fluorouracil, epirubicin, paclitaxel, albumin-bound paclitaxel). GEP results were categorized according to interpretation as low, medium, and high risk of recurrence.
Other covariates included age, menopausal status (pre or post), annual household income (<$40,000, $40,000 to $74,999, $75,000 to $124,999, ≥ $125,000), comorbidity, American Joint Committee on Cancer stage definitions (I, II, III), estrogen receptor status (positive, negative), type of surgery, and region (Northeast, Midwest, South, West).
We examined associations of patient characteristics with receipt of each of the targeted tests and treatments using bivariate analyses. Logistic regression was used to estimate adjusted odds ratios (ORs) and 95% confidence intervals (CIs). Models included all factors that we believed, a priori, could potentially be associated with these outcomes. All final models included age, menopausal status, income, health plan type, comorbidity (none, 1, or ≥ 2), disease stage, estrogen receptor status, surgery, and region. Models of trastuzumab use also included both type of HER2 test and interpreted results (negative, intermediate, positive, not done or not documented). For trastuzumab models, we separately examined use among women with and without HER2-positive cancer. Models of GEP use also included HER2 results, and models of adjuvant chemotherapy included GEP score. Analysis of GEP included women who met the Aetna coverage policy.10 In primary models of adjuvant chemotherapy, we used as reference women who fit these criteria but did not receive GEP testing. In a secondary analysis, we examined the bivariate association between GEP result and adjuvant chemotherapy use among women who had received GEP testing. We did not perform multivariate analyses because of the relatively small sample size. In exploratory analysis of race/ethnicity, this variable was coded as white versus nonwhite in the models. Analyses were performed using STATA version 10 (StataCorp, College Station, TX).
Median age was 54 years, and a majority of women were postmenopausal (). Approximately one-third had coverage through an HMO. Seventy-seven percent had no comorbid conditions. Breast cancer was diagnosed as stage I for 57.9%, stage II for 33.0%, and stage III for 9.0%. Poorly and moderately differentiated tumors were somewhat more common than well differentiated. A majority of tumors were estrogen receptor positive. Women lived in all 4 regions of the United States, with the most in the South (50.1%) and fewest in the West (11.0%).
HER2 Testing Strategies
Only 3.1% of women did not have documentation of any HER2 test. The most common testing strategy was IHC (57.9%), with 19.6% of women receiving FISH and 22.4% receiving both. Use of HER2 testing was uniform across both clinical and nonclinical factors (data not shown).
Use of Trastuzumab
Overall, 13.4% of women received trastuzumab. Type of HER2 test and result were strongly associated with utilizan tion (P <.001). Approximately one-fourth of women who received trastuzumab did not have documentation of a positive HER2 test. Among women without an HER2-positive test, 25 (3.9%) received trastuzumab. In these women, those who had undergone mastectomy were more likely than women who had had breast-conserving surgery to receive trastuzumab (OR, 2.83; 95% CI, 1.20 to 6.65). There was also a trend (P < .10) toward women in an HMO being more likely than those with other plan types to receive trastuzumab (OR, 2.69; 95% CI, 0.92 to 7.91).
Among women with an HER2-positive result, 57.7% received trastuzumab (). Even among those with larger tumors (>2 cm), 25.9% of HER2-positive women did not receive trastuzumab. After adjustment, women with an annual household income less than $40,000 were more likely to receive trastuzumab than women with an income of $125,000 or greater (OR, 4.43; 95% CI, 1.22 to 16.04).
Use of GEP
Among the 393 clinically eligible women, 24.9% received GEP (). All women in this sample underwent GEP testing using Oncotype DX. There was no significant difference in GEP use before and after implementation of the Aetna coverage policy (26.8% and 20.4%, respectively; P = .18). Among women who received GEP, 66.3% were characterized as having a low risk of recurrence; 24.7%, intermediate risk; and 9.0%, high risk. Use of GEP was less common among lower-income women. Women in the Midwest were more likely to receive GEP testing than women in the South. There was no significant variation in use of GEP by age, plan type, menopausal status, comorbidity, cancer stage, type of surgery, or HER2 result. In secondary analyses, nonwhite women were less likely to receive GEP (OR, 0.48; 95% CI, 0.24 to 0.95). We found a trend toward less GEP use after the coverage policy change (OR, 0.59; 95% CI, 0.34 to 1.04).
Use of Chemotherapy
Among women clinically eligible for GEP, 38.9% received adjuvant chemotherapy (Table 3). Use of chemotherapy decreased with age and increased with stage. Notably, use of chemotherapy increased as GEP score indicated a higher recurrence risk, yet almost one-fourth of women with a low recurrence score received chemotherapy. Although women with a low recurrence score were not statistically less likely than women who did not undergo GEP testing to receive chemotherapy (OR, 0.55; 95% CI, 0.26 to 1.16; P = .12), those with an intermediate or high score were more likely to do so. The coverage policy change for GEP testing was not associated with use of adjuvant chemotherapy (OR, 1.25; 95% CI, 0.73 to 2.21).
More Recent Trends
Because use of GEP and trastuzumab may be evolving, we wanted to place our medical record data from 2006 to 2008 in the context of information about care provided more recently, using claims. We found that claims for GEP increased substantially through 2009 (2007, 1175 claims; 2008, 1802; 2009, 2037). Conversely, we observed a small decline in claims for trastuzumab, from 18,018 in 2007 to 17,603 in 2009.
To our knowledge, this study provides some of the first real-world evidence of how targeted tests and treatments are being used in clinical practice for insured women with early stage breast cancer. We demonstrate that HER2 testing is widely used. Although a majority of women who received trastuzumab had documentation of an HER2-positive test, approximately one-fourth did not, suggesting that there may be incomplete documentation of test results or overuse of this expensive treatment. Among women with an HER2-positive tumor, many did not receive trastuzumab, despite insurance coverage. Although some of these women had small nodenegative tumors or substantial comorbidity, others may have been undertreated or deferred this treatment. In contrast to the near-universal adoption of HER2 testing, we found more modest use of GEP, perhaps because of lack of guidelines recommending universal use, newness of the test, and less straightforward treatment implications. We also found evidence for unexplained socioeconomic and regional differences in use. Finally, we found that GEP results are being used to tailor use of adjuvant chemotherapy, independent of traditional clinical factors.
This study addresses important gaps in evidence regarding utilization of HER2 testing and trastuzumab.25 On a positive note, virtually all women received an HER2 test, consistent with guidelines8-10 and similar to results of a study of 322 commercial health plan members from 2005 to 2006.2 Use of trastuzumab in our study was lower than the rate of 70.8% described in this cohort of commercial health plan members2 and the rate observed in a region of the United Kingdom,26 but it was higher than the rate observed in an earlier study involving a single healthcare provider.27 We do not know why some eligible women did not have documentation of use. Because all of these women had coverage for this therapy, it is likely that this finding is related to nonfinancial barriers to care. Related work has shown that women with breast cancer may not receive conventional adjuvant chemotherapy because of physician perception that the risks exceed the benefits, patient refusal, or system failures.28 There is also concern among both patients and providers about the reliability and interpretation of HER2 testing and uncertainty about who will benefit most from trastuzumab.9,11,12,29,30 Finally, we do not have a definitive explanation for the counterintuitive finding that low-income women were most likely to receive trastuzumab, but we suspect this is related to factors that we did not measure (eg, employment status). Our finding that one-fourth of women did not have documentation of a positive result, possibly indicating overuse, is consistent with other estimates.31
In contrast to the widespread use of HER2 testing, use of GEP was more modest. This is not surprising given the more recent availability of and coverage for the test. Analysis of more recent claims data shows that GEP use is increasing, reflecting the incorporation of GEP into clinical guidelines and the decision of several high-profile insurers to provide coverage.32 Although the test costs approximately $3400, testing may reduce the number of low-risk women receiving adjuvant chemotherapy, which costs, on average, $10,000 per patient.32 Little is known about use of adjuvant chemotherapy after GEP testing. Gold et al33 examined data for 269 women with early stage breast cancer seen at a single cancer center and found that adjuvant chemotherapy was administered to 7% of women with a low recurrence score, compared with 42% and 86% of women with intermediate and high recurrence scores, respectively. Several studies have suggested that making chemotherapy treatment decisions based on GEP is more cost effective compared with traditional risk-stratification measures.17,32,34 However, these findings should be confirmed more broadly.
Our study has several limitations. First, our data based on medical records may have incomplete information about whether tests and treatments were discussed but declined or just not documented. Second, household income and race/ethnicity information was derived largely from small area estimation.35 We cannot address reasons for observed differences in use by income or race/ethnicity; because all of these women had insurance, differences are likely to be related to nonfinancial barriers. Third, because our data were based on retrospective medical record review, we cannot determine how physicians weigh GEP test results compared with traditional measures of recurrence risk. Finally, all women received coverage from a single large health insurer, which limits the generalizability of our findings to women with public insurance, the uninsured, or older women covered by Medicare. Despite this limitation, our sample is large and geographically diverse, and it represents a variety of practice settings. As such, it provides a snapshot of how targeted technologies and treatments for breast cancer are being used in the United States. Because these data are based on medical records, we are better able to capture test usage than studies that rely solely on claims,36 and we have test results, which are critical to determining appropriate treatment.
As targeted tests and treatments become more central to cancer care, it is crucial that we develop evidence about use of these costly technologies in practice. To our knowledge, this study provides some of the first evidence about use of targeted testing and treatment for breast cancer and finds that although there is near-universal use of HER2 testing, many women who are HER2 positive may not receive trastuzumab. These findings should inform models of care and policies to ensure appropriate use of these emerging technologies.
We thank Mike Morris and Carolyn Jevit for assistance with cohort identification, database development, and claims data preparation. The study was supported by the Aetna Foundation and National Cancer Institute (Grant No. P01CA130818-01A1).
Authors’ Disclosures of Potential Conflicts of Interest: Although all authors completed the disclosure declaration, the following author(s) indicated a financial or other interest that is relevant to the subject matter under consideration in this article. Certain relationships marked with a “U” are those for which no compensation was received; those relationships marked with a “C” were compensated. For a detailed description of the disclosure categories, or for more information about ASCO’s conflict of interest policy, please refer to the Author Disclosure Declaration and the Disclosures of Potential Conflicts of Interest section in Information for Contributors.
Employment or Leadership Position: Joanne Armstrong, Aetna (C); Michele Toscano, Aetna (C). Consultant or Advisory Role: None. Stock Ownership: Joanne Armstrong, Aetna; Michele Toscano, Aetna. Honoraria: None. Research Funding: Jennifer S. Haas, Aetna Foundation; Kathryn A. Phillips, Aetna Foundation; Su-Ying Lian, Aetna Foundation; Carol Keohane, Aetna Foundation. Expert Testimony: None. Other Remuneration: None.
Conception and design: Jennifer S. Haas, Kathryn A. Phillips, Su-Ying Liang, Michael J. Hassett, Carol Keohane, Elena B. Elkin, Joanne Armstrong, Michele Toscano. Financial support: Jennifer S. Haas, Kathryn A. Phillips Administrative support: Jennifer S. Haas, Kathryn A. Phillips, Joanne Armstrong, Michele Toscano. Provision of study materials or patients: Joanne Armstrong, Michele Toscano. Collection and assembly of data: Jennifer S. Haas, Kathryn A. Phillips, Su-Ying Liang, Michael J. Hassett, Carol Keohane, Elena B. Elkin, Joanne Armstrong, Michele Toscano. Data analysis and interpretation: Jennifer S. Haas, Kathryn A. Phillips, Su-Ying Liang, Michael J. Hassett, Carol Keohane, Elena B. Elkin. Manuscript writing: Jennifer S. Haas, Kathryn A. Phillips, Su-Ying Liang, Michael J. Hassett, Carol Keohane, Elena B. Elkin. Final approval of manuscript: Jennifer S. Haas, Kathryn A. Phillips, Su-Ying Liang, Michael J. Hassett, Carol Keohane, Elena B. Elkin, Joanne Armstrong, Michele Toscano.
Address Correspondence to: Jennifer S. Haas, MD, MSPH, Division of General Medicine and Primary Care, 1620 Tremont St, Boston, MA 02120; E-mail: Jhaas@partners.org.
1. Phillips KA: Closing the evidence gap in the use of emerging testing technologies in clinical practice. JAMA 300:2542-2544, 2008
2. Barron JJ, Cziraky MJ, Weisman T, et al: HER2 testing and subsequent trastuzumab treatment for breast cancer in a managed care environment. Oncologist 14:760-768, 2009
3. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neuoncogene. Science 235:177-182, 1987
4. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684, 2005
5. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672, 2005
6. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al: Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354:809-820, 2006
7. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001
8. Bast RC Jr, Ravdin P, Hayes DF, et al: 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19:1865-1878, 2001
9. Wolff AC, Hammond ME, Schwartz JN, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118-145, 2007
10. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Breast Cancer v. 1.2009. http://www.nccn.org/professionals/ physician_gls/f_guidelines.asp
11. Kolata G: Cancer fight: unclear tests for new drug. New York Times, April 20, 2010:A1
12. Yaziji H, Goldstein LC, Barry TS, et al: HER-2 testing in breast cancer using parallel tissue-based methods. JAMA 291:1972-1977, 2004
13. Renshaw RN: Outcomes-based access: what will it mean for biologics? Biotechnol Healthc 39-44, 2006
14. Hillner BE, Smith TJ: Do the large benefits justify the large costs of adjuvant breast cancer trastuzumab? J Clin Oncol 25:611-613, 2007
15. Barrett A, Roques T, Small M, et al: How much will Herceptin really cost? BMJ 333:1118-1120, 2006
16. Paik S, Shak S, Tang G, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817-2826, 2004
17. Goldstein LJ, Gray R, Badve S, et al: Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol 26:4063-4071, 2008
18. Albain K, Barlow W, Shak S, et al: Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal, nodepositive, ER-positive breast cancer. Presented at the 30th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 13-16, 2007
19. Paik S, Tang G, Shak S, et al: Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24:3726-3734, 2006
20. Eifel P, Axelson JA, Costa J, et al: National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst 93:979-989, 2001
21. Hassett MJ, O’Malley AJ, Pakes JR, et al: Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst 98:1108-1117, 2006
22. Aetna: Clinical policy bulletin number 352: Tumor markers. Aetna, Hartford, CT, 2009
23. Klabunde CN, Potosky AL, Legler JM, et al: Development of a comorbidity index using physician claims data. J Clin Epidemiol 53:1258-1267, 2000
24. Nielsen Claritas Update Demographics Methodology. Nielson Company, New York, NY, 2009
25. Phillips KA, Marshall DA, Haas JS, et al: Clinical practice patterns and cost effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients. Cancer 115:5166-5174, 2009
26. Coulson SG, Kumar VS, Manifold IM, et al: Review of testing and use of adjuvant trastuzumab across a cancer network: Are we treating the right patients? Clin Oncol (R Coll Radiol) 22:289-293, 2010
27. Stark A, Kucera G, Lu M, et al: Influence of health insurance status on inclusion of HER-2/neu testing in the diagnostic workup of breast cancer patients. Int J Qual Health Care 16:517-521, 2004
28. Bickell NA, LePar F, Wang JJ, et al: Lost opportunities: Physicians’ reasons and disparities in breast cancer treatment. J Clin Oncol 25: 2516-2521, 2007
29. Paik S, Bryant J, Tan-Chiu E, et al: Real-world performance of HER2 testing: National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst 94:852-854, 2002
30. Bartlett JM: Pharmacodiagnostic testing in breast cancer: Focus on HER2 and trastuzumab therapy. Am J Pharmacogenomics 5:303-315, 2005
31. Newcomer LN: Insurers and ‘targeted biologics’ for cancer: A conversation with Lee N. Newcomer—Interview by Barbara J. Culliton. Health Aff (Millwood) 27:w41-w51, 2008
32. Lyman GH, Cosler LE, Kuderer NM, et al: Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies. Cancer 109:1011-1018, 2007
33. Gold JM, Najita JS, Lester S, et al: Personalizing treatment in earlystage breast cancer: the role of standard clinical factors and genomic information in adjuvant chemotherapy decision making. Presented at the 45th Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, May 29-June 2, 2009
34. Oestreicher N, Ramsey SD, Linden HM, et al: Gene expression profiling and breast cancer care: what are the potential benefits and policy implications? Genet Med 7:380-389, 2005
35. Krieger N, Chen JT, Waterman PD, et al: Painting a truer picture of US socioeconomic and racial/ethnic health inequalities: the Public Health Disparities Geocoding Project. Am J Public Health 95:312-323, 2005
36. Tong KB, Chen E, Kim GD: HER2 testing and trastuzumab use in the Medicare population. Presented at the 2007 Breast Cancer Symposium, San Francisco, CA, September 7-8, 2007